Ono Pharmaceutical Co Ltd (OPHLY) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Ono Pharmaceutical Co Ltd stock $7.86, price $4.91, upside +60.0%, quality 80 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $2.94 – $7.64 · fair‑value band $5.89 – $9.82 · the $4.91 price screens below the $7.86 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Ono Pharmaceutical Co in your weekly email
Every Wednesday you see whether Ono Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide.
Show moreShow less
It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia.
The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis.
In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis.
The company has collaborations with Adimab LLC; Turbine Ltd.; Harvard University; Sibylla Biotech; and Congruence Therapeutics. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
Stock analysis
Ono Pharmaceutical Co Ltd (OPHLY) currently trades at $4.91, while our model-based Fair Value estimate is $7.86, implying the stock looks roughly 38% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $11.95 per share, and 20 of the 26 models we run sit above the $4.91 price.
Bear case: the Asset-Based group reads lowest at $0.9600, and 6 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $5.89 (bear) to $9.82 (bull), the price of $4.91 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 80/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Ono Pharmaceutical Co Ltd reported revenue of ¥547B in FY2026 versus ¥361B in FY2022, a compound +10.9%/yr. Reported net income was ¥74.0B in FY2026, compounding −2.1%/yr from FY2022.
Key figures
Market cap $6.9B Mid · P/E ratio 14.0 · P/S ratio 1.90 · EPS (TTM) $0.3500 · Dividend yield 3.2% · Net margin 13.5% · Return on equity 9.3% · Return on assets (EBIT) 12.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 62 out of 100 (low confidence).
What moves the price
The share trades about 10% below its 52-week high and 26% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at 60%, OPHLY screens cheaper than that median.
Fair Value models
Bear$5.89Fair Value $7.86Bull$9.82
Price $4.91 · Upside +60.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then ($0.2129 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF$8.76$14.44$24.0678
Growth DCF$8.84$14.43$24.0076
Residual Income$3.31$3.61$4.3076
All 26 models by family
DCF Models
FCF DCF$8.76$14.44$24.0678
Owner Earnings$8.29$13.64$22.7074
5Y Revenue Exit$6.26$9.45$13.5672
5Y EBITDA Exit$7.64$12.15$17.5575
5Y P/E Exit$6.67$10.27$14.1571
10Y Revenue Exit$6.88$10.14$14.6567
10Y EBITDA Exit$7.95$12.10$17.8968
10Y P/E Exit$7.31$10.73$15.1364
Earnings-Based
Graham-Dodd$2.25$8.54$11.5664
Lynch FV$2.07$2.96$3.8561
PEG = 1.0$2.07$2.96$3.8557
EPV$4.55$5.22$5.8274
Dividend Discount
Gordon GGM$1.71$3.73$6.2765
DDM Multi-Stage$1.71$3.06$3.8966
Multiples
P/E Multiple$5.46$7.29$9.1163
P/S Multiple$4.22$5.63$7.0458
P/B Multiple$7.20$9.60$12.0055
EV/EBIT$6.78$8.86$10.9566
EV/EBITDA$7.55$9.90$12.2467
EV/Revenue$4.99$6.90$8.8154
Asset-Based
NCAV (Graham)$0.6300$0.9600$1.1955
Growth DCF
Growth DCF$8.84$14.43$24.0076
Rev-Margin DCF$6.26$9.47$13.3872
Economic Profit
Residual Income$3.31$3.61$4.3076
ROIC Compounder$4.81$6.24$8.2372
Growth Earnings
Growth-Adj P/E$3.90$5.57$7.2467
The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.91/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+12.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.1%
Start year 2021 (pandemic). Over 10 years: +13.1% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in JPY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+28.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+25.6%
Dividend (yield on the price)3.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.25.6% vs 25.9%, steady
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.32% → 20%
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−12.0%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
−4.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in JPY, Japan: IMF forecast 2.1% a year to 2030, 1.3% from 2016 to 2025) that is about −13.8% a year for the price and −6.7% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (61 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
AI conclusion: Limited external signals and an ROE of 8.7 percent give little proof of durable advantage, while high gross margins offer modest evidence of pricing power in standard pharma operations.
Main risk: The expiration of patents on Opdivo, a major revenue driver, could reduce sales and margins without an offsetting product pipeline.
Bull case: Ono could leverage its AI collaborations and global expansion via the Deciphera acquisition to build a diversified pipeline that offsets Opdivo losses and accelerates the Biohaven assets to market.
Bear case: If Opdivo revenues decline sharply after 2028 and the Biohaven assets face delays or strong competition from Immunovant, Ono’s growth in immunology could stall amid higher development costs.
Ono recently gained exclusive Asian rights to Biohaven's IgG degrader portfolio, including a Phase 3 candidate for Graves' disease. The deal bolsters its immunology focus with a novel mechanism yet brings upfront costs and the need to handle local development and approvals. Will these assets expand Ono's reach in autoimmune diseases faster than they add execution complexity?
Compare Ono Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks
Beats the industry median on 11/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score80 · Top 25%
Fair Value upside+60.0% · Top 25%
Profitability
Return on equity (12 months)9.3% · Below median
Return on assets6.7% · Below median
Net margin (12 months)15.1% · Above median
Operating margin (12 months)26.4% · Above median
Growth and dividend
Revenue growth (quarter YoY)−8.9% · Bottom 25%
Dividend yield (12 months)3.2% · Top 25%
Balance sheet
Debt / equity0.09× · Below median
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Ono Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/OPHLY
Frequently asked questions
Is Ono Pharmaceutical Co Ltd (OPHLY) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $7.86 versus a price of $4.91, about +60% upside (undervalued).
What is the fair value of OPHLY?
Our model-based fair value for Ono Pharmaceutical Co Ltd is $7.86 (as of Nov 6, 2026), built from audited fundamentals. The current price: $4.91.
What is the quality score of OPHLY?
Ono Pharmaceutical Co Ltd has a Quality Score of 80/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ono Pharmaceutical Co Ltd (OPHLY)?
Our model-based price target is the fair value of $7.86 (as of Nov 6, 2026) from 26 valuation models. Cautious scenario $5.89, optimistic scenario $9.82. It is a calculation from audited fundamentals, not an analyst target.
What is the Ono Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at $7.86, about +60% upside versus a price of $4.91 (undervalued). Cautious scenario $5.89, optimistic scenario $9.82. The calculation is refreshed regularly with new filings.
What is the revenue of Ono Pharmaceutical Co Ltd (OPHLY)?
Ono Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about ¥504B (latest available figure, as of Nov 6, 2026).
Does Ono Pharmaceutical Co Ltd pay a dividend?
Ono Pharmaceutical Co Ltd currently shows a dividend yield of 3.20% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Ono Pharmaceutical Co Ltd (OPHLY) and when is the ex-dividend date?
Ono Pharmaceutical Co Ltd has a dividend yield of 3.2%. The last ex-dividend date was Mar 31, 2026. A dividend has been paid every year since at least 2012. The payout ratio is 47.4% of earnings. Free cash flow covers the dividend 3.95 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Ono Pharmaceutical Co Ltd (OPHLY)?
For today's price to be fair in a discounted-cash-flow model, Ono Pharmaceutical Co Ltd would have to grow free cash flow by -12.0 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.1 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of OPHLY use?
Our models discount Ono Pharmaceutical Co Ltd at 8.5 %: a base by market capitalisation (mid), damped by beta 0.14, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Ono Pharmaceutical Co Ltd that is -12.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Ono Pharmaceutical Co Ltd (OPHLY) delivered so far?
Over the past 5 years revenue at Ono Pharmaceutical Co Ltd grew +12.1 % a year. The price currently implies free-cash-flow growth of -12.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Ono Pharmaceutical Co Ltd (OPHLY) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Ono Pharmaceutical Co Ltd (-12.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Ono Pharmaceutical Co Ltd (OPHLY)?
The free-cash-flow yield on the price is 12.65 %: that much free cash flow Ono Pharmaceutical Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Ono Pharmaceutical Co Ltd (OPHLY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ono Pharmaceutical Co Ltd it is $7.86 per share (as of Nov 6, 2026), against a price of $4.91. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Ono Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Nov 6, 2026, OPHLY trades below its calculated fair value: price $4.91, fair value $7.86, a gap of about +60% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OPHLY?
No. The price is what the market pays today ($4.91); the fair value is what the company's own numbers justify ($7.86). For Ono Pharmaceutical Co Ltd the two are $2.95 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ono Pharmaceutical Co Ltd worth?
The market values Ono Pharmaceutical Co Ltd at about $6.9B (market capitalisation, as of Nov 6, 2026). Per share that is $4.91; our models calculate a fair value of $7.86 per share.
What do the bullish and bearish scenarios say about OPHLY?
Our models span a range for Ono Pharmaceutical Co Ltd: cautious scenario $5.89, base $7.86, optimistic $9.82 per share (as of Nov 6, 2026, price $4.91). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of OPHLY?
Ono Pharmaceutical Co Ltd trades at a price-to-earnings ratio of 14.0 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $7.86 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2017 to 2026), reported earnings: 57.0. Other multiples: P/B 1.3, P/S 2.2, EV/EBITDA 6.8.
How solid is the balance sheet of Ono Pharmaceutical Co Ltd (OPHLY)?
Balance-sheet figures for Ono Pharmaceutical Co Ltd (as of Nov 6, 2026): return on equity 9.3%, debt of 0.09 per unit of equity. They feed the Quality Score of 80/100, which measures business quality independently of the share price.
How far is OPHLY from its 52-week high?
Ono Pharmaceutical Co Ltd trades at $4.91, about 10% below its 52-week high of $5.43 and 26% above the low of $3.89 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $7.86 is for.
Which stocks are comparable to Ono Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ono Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Nov 6, 2026: price $4.91, calculated fair value $7.86 (+60%), Quality Score 80/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OPHLY calculated?
We run Ono Pharmaceutical Co Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $7.86 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Ono Pharmaceutical Co Ltd currently trades 38% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ono Pharmaceutical Co Ltd (OPHLY)?
The closing price on Nov 6, 2026 was $4.91. Our model-based fair value is $7.86, about +60% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ono Pharmaceutical Co Ltd right now?
The rarer combination: high quality (80/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case ($5.89). The market is more pessimistic than our downside scenario.
Where does the earnings growth of Ono Pharmaceutical Co Ltd (OPHLY) come from?
Earnings per share at Ono Pharmaceutical Co Ltd grew +27.7 % a year from 2015 to 2026. Broken into its drivers: revenue per share +28.5 %, EBIT margin −0.1 %, tax rate +0.5 %, residual (interest, one-offs) −1.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Ono Pharmaceutical Co Ltd
How large is the market capitalisation of Ono Pharmaceutical Co Ltd (OPHLY)?
The market capitalisation of Ono Pharmaceutical Co Ltd is $6.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ono Pharmaceutical Co Ltd (OPHLY)?
The price-to-sales ratio of Ono Pharmaceutical Co Ltd is 1.90 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ono Pharmaceutical Co Ltd (OPHLY)?
Earnings per share at Ono Pharmaceutical Co Ltd are $0.3500 (price ÷ EPS = P/E 14.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Ono Pharmaceutical Co Ltd (OPHLY)?
The dividend yield of Ono Pharmaceutical Co Ltd is 3.2% (payout 44.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Ono Pharmaceutical Co Ltd (OPHLY)?
The net margin of Ono Pharmaceutical Co Ltd is 13.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ono Pharmaceutical Co Ltd (OPHLY)?
The return on equity (ROE) of Ono Pharmaceutical Co Ltd is 9.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ono Pharmaceutical Co Ltd (OPHLY)?
On an EBIT basis the return on assets of Ono Pharmaceutical Co Ltd is 12.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ono Pharmaceutical Co Ltd (OPHLY)?
The operating margin of Ono Pharmaceutical Co Ltd is 26.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ono Pharmaceutical Co Ltd (OPHLY)?
Revenue at Ono Pharmaceutical Co Ltd is growing −8.9% versus a year earlier (3y avg +6.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ono Pharmaceutical Co Ltd (OPHLY)?
Earnings per share at Ono Pharmaceutical Co Ltd are growing +36.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Ono Pharmaceutical Co Ltd (OPHLY) hold?
Ono Pharmaceutical Co Ltd holds more cash than debt, ¥117B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Ono Pharmaceutical Co Ltd in the live analysis
One click puts Ono Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026